

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dianne Angus
Date of last notice	12 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	21 April 2023
No. of securities held prior to change	1) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 2) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027) 3) 243,000 Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	3) 80,375
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1) \$1,366.38
No. of securities held after change	1) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 2) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027) 3) 323,375 Ordinary Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	30,375 Entitlement Offer shares and 50,000 as part of Shortfall

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest after change	N/A
-----------------------	-----

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Van Asten
Date of last notice	10 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	21 April 2023
No. of securities held prior to change	<ol style="list-style-type: none"> 1) 545,000 Ordinary Shares 2) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
Class	Fully Paid Ordinary Shares
Number acquired	1) 68,125

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) \$1,158.13
No. of securities held after change	<ol style="list-style-type: none"> 1) 613,125 Ordinary Shares 2) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	68,125 Entitlement Offer shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jovanka Naumoska
Date of last notice	6 August 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	21 April 2023
No. of securities held prior to change	<ol style="list-style-type: none"> 1) 260,000 Ordinary Shares 2) 60,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
Class	Fully Paid Ordinary Shares
Number acquired	1) 32,500

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) \$552.50
No. of securities held after change	1) 292,500 Ordinary Shares 2) 60,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	32,500 Entitlement Offer shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.